Articles tagged "Immunosuppression"

2021 American Transplant Congress
Regulatory Macrophage Induced by Il-33 Promoted Immune Tolerance of Kidney Transplantation Through Siglec-10
J. d. zhang, w. wang
Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
*Purpose: Acute and chronic rejection are key problems in renal transplantation. It is ideal to induce immune tolerance to suppress rejection while regulatory macrophages (Mregs)…
2021 American Transplant Congress
Clinical Outcomes and Management of Covid-19 Patients Among Kidney Transplant Recipients: A Systematic Review
S. Ismail¹, A. Babonj², S. Al Harbi³, A. Babonj², A. Almalki¹, E. J. Murray⁴
¹King Khalid hospital, MNGHA, Jeddah, Saudi Arabia, ²King Abdulaziz University, Jeddah, Saudi Arabia, ³King Faisal Specialist Hospital, Jeddah, Saudi Arabia, ⁴Boston University School of Public Health, Boston, MA
*Purpose: We aim to systematically review published literature and synthesize the evidence available on therapeutic interventions and clinical outcomes used in the management of COVID-19…
2021 American Transplant Congress
Early Conversion to Belatacept-based Therapy Improves Graft Function in Renal Transplant Patients
N. Huang¹, C. J. Yang², I. Movileanu¹, R. H. Dvorai³, K. M. Ecal¹, R. F. Saidi¹, A. N. Ayla Senay¹, B. Gallay⁴, M. J. Hanlon¹, S. Narsipur⁴, M. R. Laftavi¹, R. Shahbazov¹
¹Surgery, SUNY Upstate Medical University, Syracuse, NY, ²Pharmacy, SUNY Upstate Medical University, Syracuse, NY, ³Pathology, SUNY Upstate Medical University, Syracuse, NY, ⁴Medicine, SUNY Upstate Medical University, Syracuse, NY
*Purpose: Our goal in this study was to assess the impact of early vs late conversion to Belatacept based (Bela) IS in kidney transplant (KT)…
2021 American Transplant Congress
Lung Transplant Outcomes Based on Immunosuppressive Regimen at Discharge: Data from the US Scientific Registry of Transplant Recipients (SRTR)
W. Fitzsimmons¹, J. Erdman², J. Wolfram³, D. Nimke², R. Croy², X. Wang², T. Weaver⁴, D. Schladt⁴
¹University of Illinois at Chicago, College of Pharmacy, Vernon Hills, IL, ²Astellas Pharma, Inc, Northbrook, IL, ³Astellas Pharma Europe BV, Leiden, Netherlands, ⁴Chronic Disease Research Group, Minneapolis, MN
*Purpose: There is currently no FDA approved immunosuppressive regimen for lung transplant (Tx) recipients; however, patients routinely receive a calcineurin inhibitor-based regimen. The SRTR database…
2021 American Transplant Congress
Validation of a Novel Gene Expression Biomarker of Rejection Following Liver Transplantation
J. Levitsky¹, M. Kandpal¹, T. Whisenant², K. Guo¹, S. Kurian³, M. Abecassis⁴
¹Gastroenterology & Hepatology; Comprehensive Transplant Center, Northwestern University, Chicago, IL, ²University of California San Diego, San Diego, CA, ³Scripps Clinic, La Jolla, CA, ⁴University of Arizona College of Medicine Tucson, Tucson, AZ
*Purpose: Non-invasive biomarkers distinguishing early signs of immune activation vs. quiescence could more objectively guide immunosuppression management after liver transplantation (LT). Our aim was to…
2021 American Transplant Congress
PD-1/PD-L1 Selectively Regulates Treg Lymphatic Migration
W. Piao¹, L. Li¹, C. Paluskievicz¹, Y. Zhang², V. Saxena³, K. Hippen², B. Blazar², L. Riella⁴, J. Bromberg¹
¹Surgery, U Maryland, Baltimore, MD, ²U Minnesota, Minneapolis, MN, ³U Maryland, Baltimore, MD, ⁴Harvard U, Boston, MA
*Purpose: The molecules that regulate Treg migration are incompletely identified. Programmed death-1 (PD-1) and its ligand PD-L1 are immune checkpoint proteins which regulate immune cell…
2021 American Transplant Congress
Complement Blockade Improves Renal Xenograft Survival in Primates in the Absence of Transgenic Complement Regulatory Proteins
D. A. Faber¹, B. Lovasik¹, A. Matar¹, C. Breeden¹, A. B. Farris², M. Tector³, A. Tector³, A. Adams⁴
¹Surgery, Emory University School of Medicine, Atlanta, GA, ²Pathology, Emory University School of Medicine, Atlanta, GA, ³Surgery, University of Miami, Miami, FL, ⁴Surgery, University of Minnesota, Minneapolis, MN
*Purpose: Complement activation is a major contributor to xenograft rejection. To minimize xenograft injury, complement suppression via insertion of human complement-regulatory transgenes into the donor…
2021 American Transplant Congress
Transforming Growth Factor-Beta Induced Myeloid-Derived Suppressor Cells Promote Transplant Immune Tolerance
F. Zhang
Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China, Beijing, China
*Purpose: Myeloid-derived suppressor cells (MDSCs) are a group of heterogeneous cells derived from bone marrow with immunosuppressive effect, which contribute to the establishment of transplant…
2021 American Transplant Congress
Impact of Belatacept and Tacrolimus on Cmv Viral Load Control and Relapse in Moderate and High-risk Cmv Serostatus Kidney Transplant Recipients
W. Magua¹, A. C. Johnson¹, G. M. Karadkhele¹, I. R. Badell¹, P. Vasanth¹, M. G. Lyon III², A. K. Mehta², K. A. Easley³, J. Rickert⁴, C. P. Larsen¹
¹Department of Surgery, Emory University, Atlanta, GA, ²Department of Medicine, Emory University, Atlanta, GA, ³Biostatistics and Bioinformatics, Emory University, Atlanta, GA, ⁴RStudio and R Consortium, San Jose, CA
*Purpose: We aim to evaluate the impact of belatacept and tacrolimus on CMV viral load control, remission and relapse in CMV high-risk (serostatus, D+/R-) and…
2021 American Transplant Congress
Belatacept Utilization During the Covid-19 Pandemic in the United States
M. MacConmara, A. Shubin, D. Wojciechowski, L. de Gregorio, J. Shah, P. Vagefi, C. S. Hwang
Department of Surgery, Division of Surgical Transplantation, University of Texas Southwestern Medical Center, Dallas, TX
*Purpose: With the onset of the COVID-19 pandemic, many people in the United States were urged to stay at home. Kidney transplantation continued during this…